The message, so odd before, is now standard. Some cholesterol is good, and low levels of high-density lipoprotein (HDL) have repeatedly been implicated in cardiovascular disease. When the ABC1 transporter was found to be associated in the HDL deficiency of patients with Tangier disease, 1 scientists began developing models of cholesterol transport to the protective lipoproteins. But, no one had shown the genes involved in transporting cholesterol from arterial macrophages to HDL particles. While high hopes surrounding an HDL-elevating drug were bolstered by one of the Hot Papers featured here, trials in humans were halted prematurely due to higher risk of death in people taking the drug.
Survey Series
For Advertisers
Cholesterol's ABCs
Two studies highlight targets for raising HDL.
(continued >>)
To continue reading this full article, you must be a subscriber to The Scientist.
You are only a few minutes away from unlimited access.
If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
Subscribe to The Scientist to get unlimited access to our premium content
Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95. Subscribe now.The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.